Premium
A case of hepatosplenic γ – δ T‐cell lymphoma with a transient response to Fludarabine and Alemtuzumab
Author(s) -
Mittal S.,
Milner B. J.,
Johnston P. W.,
Culligan D. J.
Publication year - 2006
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2006.00646.x
Subject(s) - alemtuzumab , fludarabine , medicine , lymphoma , chemotherapy , regimen , oncology , surgery , cyclophosphamide , transplantation
Hepatosplenic γ – δ T‐cell lymphoma is a rare, usually fatal lymphoma and available literature on management is sparse. Allografting is probably the only curative option. We describe a further case with a dramatic, though transient response to Fludarabine and Alemtuzumab combination, following a failure of conventional chemotherapy. Given the dreadful prognosis with conventional chemotherapy, it is a regimen worth pursuing as a disease reduction strategy prior to allograft where appropriate.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom